Regulatory
Direct-to-Consumer Genomics in the Crosshairs![](https://eu-images.contentstack.com/v3/assets/blt09e5e63517a16184/bltafc06db067aebac6/64cbf83cdb0bcc7a8de33eaa/NewHopeNetwork_Horizontal_RGB.png?width=700&auto=webp&quality=80&disable=upscale)
Industry Insights![](https://eu-images.contentstack.com/v3/assets/blt09e5e63517a16184/bltafc06db067aebac6/64cbf83cdb0bcc7a8de33eaa/NewHopeNetwork_Horizontal_RGB.png?width=700&auto=webp&quality=80&disable=upscale)
Direct-to-Consumer Genomics in the CrosshairsDirect-to-Consumer Genomics in the Crosshairs
Personal genomics seemed to be on a rocketship trajectory until the FDA sent a warning letter to 23andMe questioning marketing materials that bordered on self diagnosis.
Subscribe and receive the latest updates on trends, data, events and more.
Join 57,000+ members of the natural products community.